Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Medix Biochemica Launches MedixMAB by Design™ at AACC 2013

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
Highest quality recombinant antibody production service to ensure superior IVD tests.

Medix Biochemica announces the launch of its MedixMAB by Design™ antibody production service, at the annual AACC meeting in Houston, USA, 28 July – 1 August, 2013 (Booth 3606). Offering a completely customised service for the in vitro generation of high-performance monoclonal recombinant antibodies and Fab fragments, MedixMAB by Design presents an excellent foundation for superior IVD assays. With antibodies produced to the strictest international quality standards, the new service equips IVD manufacturers with a competitive advantage, helping to increase sales revenue without the need to invest in costly production facilities and expertise.

The advanced production technology of the MedixMAB by Design service allows for the targeting of a broader range of antigens than possible in vivo, including poorly immunoreactive and toxic compounds, and recombinant MAB production is possible on a range of scales (mg-kg). As an alternative to producing full length MABs, Fab fragments can instead be generated in just three months, to greatly enhance specificity and sensitivity of an IVD assay in solid-phase applications. In addition to producing novel antibodies, existing antibodies can also be optimised, for example by humanisation, biotinylation or affinity maturation, for enhanced IVD test performance. Flexibility is an inherent feature of the MedixMAB by Design service, and a personal project manager provides full consultation and support throughout the process, tailoring the service to each individual need.

With the MedixMAB by Design service, high affinity recombinant antibodies exhibiting low cross-reactivity are produced using an advanced in vitro system, which incorporates the latest in cutting-edge phage display antibody production technology. To ensure the highest quality, the entire process is comprehensively regulated and documented, adhering to ISO 9001, ISO 13485 and FDA QSR quality standards. Furthermore, the in vitro production system yields a consistent level of quality between batches.

Product manager for MedixMAB by Design, Maija Partanen, commented: “With 30 years of experience in antibody production technology, Medix Biochemica provides the IVD industry with outstanding diagnostic performance. Our fast and flexible, quality-assured MedixMAB by Design service enables IVD manufacturers to offer the next generation of IVD assay, with superior sensitivity and specificity, at minimal cost.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
Blood Test Could Predict Best Treatment for Lung Cancer
Researchers at The Manchester University have isolated tumour cells that had broken away from the main cancer - known as CTCs - from the blood of 31 patients with this aggressive form of the disease.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!